Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Receivables (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Receivables for 10 consecutive years, with $159.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Receivables rose 28.23% to $159.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $159.0 million, a 28.23% increase, with the full-year FY2025 number at $159.0 million, up 28.23% from a year prior.
  • Receivables was $159.0 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $114.6 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $159.0 million in Q4 2025 to a low of $28.5 million in Q2 2021.
  • A 5-year average of $74.8 million and a median of $73.7 million in 2023 define the central range for Receivables.
  • Peak YoY movement for Receivables: tumbled 34.96% in 2021, then surged 131.82% in 2023.
  • Ultragenyx Pharmaceutical's Receivables stood at $44.4 million in 2021, then rose by 5.43% to $46.8 million in 2022, then soared by 59.01% to $74.5 million in 2023, then soared by 66.47% to $124.0 million in 2024, then increased by 28.23% to $159.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Receivables are $159.0 million (Q4 2025), $114.6 million (Q3 2025), and $125.4 million (Q2 2025).